All In Biotech

Drug Trial Radar · NCT05610202

Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects

Phase I Clinical Trial of Tolerability and Pharmacokinetics of TQB3702 Tablets in Hematologic Tumor Subjects

Last checked: Nov 19, 2026Latest source record: Nov 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

137

Planned (sponsor's estimate)

Start

Nov 2022

Primary completion

Aug 2024

Study completion Aug 2024

Sponsor

Sponsor type
Industry
First posted
Nov 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This project is an open, dose escalation and expansion phase I clinical study. The first phase is a dose escalation study, and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the tolerability and preliminary efficacy of TQB3702 tablets in hematological tumor subjects.

Conditions

  • Hematologic Malignancy

Interventions

  • TQB3702 tabletsDrug

    TQB3702 tablets are selective BTK inhibitors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD)Time frame: Baseline up to 104 weeks
  2. Dose limited toxicity (DLT)Time frame: Baseline up to 104 weeks
  3. Recommended Phase II Dose (RP2D)Time frame: Baseline up to 104 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The Cancer Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.